These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 34972579

  • 1. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
    Florent C, Beylerian M, Mairot K, Dambricourt L, André N, David T, Girard N, Audic F, Denis D.
    J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
    [Abstract] [Full Text] [Related]

  • 2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE, Nuding MA.
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [Abstract] [Full Text] [Related]

  • 3. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC.
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [Abstract] [Full Text] [Related]

  • 4. Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.
    Hepokur M, Sarici AM.
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1757-1765. PubMed ID: 29754292
    [Abstract] [Full Text] [Related]

  • 5. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
    de Blank PM, Berman JI, Liu GT, Roberts TP, Fisher MJ.
    Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
    [Abstract] [Full Text] [Related]

  • 6. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
    Falzon K, Drimtzias E, Picton S, Simmons I.
    Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
    [Abstract] [Full Text] [Related]

  • 7. The role of visual electrodiagnostics in management of children with neurofibromatosis type 1.
    Tekavčič Pompe M, Pečarič Meglič N, Šuštar Habjan M.
    Doc Ophthalmol; 2023 Apr; 146(2):121-136. PubMed ID: 36652041
    [Abstract] [Full Text] [Related]

  • 8. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
    Henning AM, Handrup MM, Kjeldsen SM, Larsen DA, Ejerskov C.
    Orphanet J Rare Dis; 2021 Nov 22; 16(1):489. PubMed ID: 34809690
    [Abstract] [Full Text] [Related]

  • 9. Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.
    Arnljots U, Nilsson M, Bolzani R, Benassi M, Sandvik U, Munoz DM, Blomgren K, Hellgren K.
    PLoS One; 2024 Nov 22; 19(7):e0305548. PubMed ID: 38990917
    [Abstract] [Full Text] [Related]

  • 10. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
    Avery RA, Bouffet E, Packer RJ, Reginald A.
    Invest Ophthalmol Vis Sci; 2013 Feb 05; 54(2):1034-8. PubMed ID: 23329671
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
    Blanchard G, Lafforgue MP, Lion-François L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y, NF France network.
    Eur J Paediatr Neurol; 2016 Mar 05; 20(2):275-281. PubMed ID: 26774135
    [Abstract] [Full Text] [Related]

  • 13. Measurements of Retinal Nerve Fiber Thickness and Ganglion Cell Complex in Neurofibromatosis Type 1, with and Without Optic Pathway Gliomas: A Case Series.
    Sahinoglu-Keskek N, Altan-Yaycioglu R, Canan H, Coban-Karatas M, Erbay A, Yazıcı N, Alkan O.
    Curr Eye Res; 2018 Mar 05; 43(3):424-427. PubMed ID: 29185816
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
    de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.
    J Neuroophthalmol; 2017 Sep 05; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
    [Abstract] [Full Text] [Related]

  • 17. Neurofibromatosis 1-associated optic pathway gliomas.
    Shofty B, Ben Sira L, Constantini S.
    Childs Nerv Syst; 2020 Oct 05; 36(10):2351-2361. PubMed ID: 32524182
    [Abstract] [Full Text] [Related]

  • 18. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
    Sharafi P, Varan A, Ersoy-Evans S, Ayter S.
    Childs Nerv Syst; 2024 Feb 05; 40(2):511-515. PubMed ID: 37401974
    [Abstract] [Full Text] [Related]

  • 19. A novel stop-gain NF1 variant in neurofibromatosis type 1 and bilateral optic atrophy without optic gliomas.
    Fukunaga N, Hayashi T, Yamada Y, Mizobuchi K, Ohta A, Nakano T.
    Ophthalmic Genet; 2024 Apr 05; 45(2):186-192. PubMed ID: 37599594
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.